You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

14 Results
Guidelines and Advice
Status: Archived
ID: 6-8
Version: 3
Mar 2015
Guidelines and Advice
Status: Archived
ID: 14-1
Jan 2015
Guidelines and Advice
Status: Education and Information
ID: GL-C50-23-V1
Version: 2
Dec 2015
Drug Safety & Advice
Jul 2015
Guidelines and Advice
Status: Current
ID: GL-C50-21
Jul 2015
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    relugolix
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
relugolix
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Drug
Other Name(s): Orgovyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Jun 2025
Drug
Other Name(s): Rituxan® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Jun 2025

Pages